Rechallenge temozolomide in glioma: A case series from India.

摘要: INTRODUCTION: Temozolomide (TMZ) is an integral part of upfront treatment high-grade gliomas. It administered postsurgery as concurrent therapy with radiation and subsequently adjuvant chemotherapy for 6–12 cycles. unknown whether rechallenge salvage TMZ in previously treated glioma has any efficacy. MATERIAL AND METHODS: Patients rechallenged between January 2015 August 2016 were included this retrospective analysis. SPSS version 20 was used Time to event analysis performed using the Kaplan–Meier method. Progression-free survival (PFS) overall (OS) estimated. The maximum grade toxicity noted accordance CTCAE 4.02. RESULTS: A total 23 patients selected median age being 43 years (range: 26–69 years). tumor histopathology at baseline astrocytoma Grade 2 1 patient, oligodendroglioma 3 patients, anaplastic 7 glioblastoma 10 patients. All them had received TMZ. numbers previous cycles 6 (4–18). time failure postlast 24 months (5–72 months). number 1–18). 3–4 myelosuppression seen (13.4%). PFS 459 days (95% confidence interval: 212.1–705.9). OS 25 months. Six-month 1-year 81.4% 75.1%, respectively. CONCLUSION: Rechallenge recurrent that responded associated improvement a sufficiently long disease-free interval.